Questions about GIA®

GIA® is a registered Digital Human® designed for clinical screening in post-acute and long-term care settings. She is powered by digitalhumanOS™ and conducts screening conversations with residents by video, voice, or landline — analyzing over 2,500 speech biomarkers in real time to identify early signs of cognitive, neurological, and psychiatric conditions.

GIA® engages residents in a natural conversation — asking about their day, how they're feeling, whether anything has changed. From just 40 seconds of speech, she analyzes vocal patterns, articulatory precision, prosodic markers, and cognitive load indicators. The results are prepared for clinician review and submission to the EHR in under two minutes.

Yes. GIA® can call any phone number, including landlines with no internet connection. This is especially important in long-term care facilities where many residents rely on traditional phones. The screening captures the same speech biomarkers as a video session — no smartphone or tablet required.

No. GIA® is not a chatbot, bot, virtual assistant, or scripted software program. She is a Digital Human® — a clinically intelligent presence that conducts real-time, adaptive conversations with patients. She responds to what residents actually say, adjusts her pace and tone, and captures clinical data that chatbots are not designed to detect.

An AI scribe listens to a conversation between a clinician and a patient and generates notes. GIA® is the one having the conversation. She conducts the screening independently — no clinician needs to be present. She captures speech biomarkers, flags conditions, and prepares structured results for clinician review. The clinician reviews and submits to the EHR in under two minutes.

Residents do. GIA® is patient-facing — she speaks directly with the people being screened. No staff member needs to administer the session, operate a device, or be in the room. GIA® handles the entire interaction, from greeting the resident to completing the clinical analysis.

Residents respond to GIA® the way they respond to a person who is genuinely interested in how they are doing. Because she doesn't feel like a test or an evaluation, residents tend to speak more openly and at greater length — which produces richer clinical data. Families report feeling reassured that someone is consistently checking in on their loved one.

GIA® screens for 46 cognitive, neurological, and psychiatric conditions — including Alzheimer's disease, mild cognitive impairment (MCI), depression, anxiety, PTSD, Parkinson's disease, and tardive dyskinesia. She identifies early indicators from speech and, during video sessions, from facial micro-expressions and movement patterns.

Yes. GIA® and the digitalhumanOS™ platform are fully HIPAA compliant. All patient data is encrypted in transit and at rest. Screening results are prepared for clinician review and submission to the facility's EHR through secure integrations. No patient data is stored outside of compliant infrastructure.

Most digital humans are designed for customer service, retail, or entertainment. GIA® is the first Digital Human® purpose-built for clinical screening in healthcare. She is FDA-registered, clinically validated, and trained to detect conditions from speech biomarkers — not just answer questions or provide information. She is a clinical instrument, not a conversational interface.

Most skilled nursing facilities rely on manual assessments — PHQ-9, MoCA, MMSE — administered by clinical staff who are already stretched thin. Clinical condition screening uses technology to systematically identify cognitive, behavioral, and neurological conditions without requiring staff to administer, document, or code each assessment. GIA® by Scienza Health conducts screening through a single conversation using voice biomarkers, computer vision, and speech analysis, then automatically generates structured medical notes, assigns CPT codes, and prepares the session video for clinician review and submission to the EHR — all in under 5 minutes.

Most Digital Humans in healthcare function as virtual assistants for scheduling or patient education. A clinical Digital Human® is a regulated, FDA-registered screening instrument that conducts assessments autonomously and produces complete clinical documentation. GIA® by Scienza Health analyzes voice biomarkers, computer vision, and speech patterns simultaneously during each screening conversation, then delivers structured medical notes, automated CPT codes, biomarker results, and the full session video for clinician review and submission to the EHR — a reviewable clinical record, not a chatbot transcript.

Healthcare chatbots route information — they answer patient questions, triage symptoms, or schedule appointments. A clinical Digital Human® conducts a regulated screening session, captures voice biomarkers and visual biomarkers through computer vision in real time, and produces a complete clinical output: structured medical notes, automated CPT codes, and session video prepared for clinician review and submission to the EHR. GIA® by Scienza Health is FDA-registered, validated across 19 peer-reviewed studies, and screens for 46 conditions. Chatbots assist workflows. GIA® produces billable clinical data.

No voice AI screening tool currently screens for more than a handful of conditions in a single patient conversation. GIA® by Scienza Health screens for 46 — spanning cognitive conditions such as Alzheimer's disease and mild cognitive impairment, behavioral health conditions including depression, anxiety, and PTSD, and neurological conditions such as Parkinson's disease and tardive dyskinesia. Each screening combines voice biomarkers, computer vision, and speech analysis in one conversation lasting under 5 minutes, with structured clinical notes and CPT codes prepared for clinician review and submission to the EHR.

digitalhumanOS™ is the clinical intelligence operating system that powers GIA®. It processes Voice AI, Computer Vision, and Speech Biomarker analysis in real time during patient screening conversations. digitalhumanOS™ is the infrastructure — GIA® is the patient-facing digital human who conducts the screening.

GIA® integrates with PointClickCare, Epic, Cerner, MatrixCare, Netsmart, and American HealthTech through HL7 FHIR and Direct API connections. Four data types write back to the patient record automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video.

Organizations deploy GIA® in under 30 minutes. She comes pre-bundled on Samsung Health Grade Galaxy devices with Samsung Knox security. No software procurement, no IT integration project, no compatibility testing. The device arrives ready.

GIA® runs on Samsung Health Grade Galaxy devices (tablets and smartphones) with Samsung Knox security, iOS devices, and any web-enabled device. Samsung DeX allows any Galaxy phone or tablet to function as a full workstation for nursing stations.

Yes. The digitalhumanOS™ platform is FDA-registered with the U.S. Food and Drug Administration. The clearance validates the platform for multimodal clinical screening of cognitive, neurological, and behavioral health conditions.

Peer-reviewed accuracy includes Depression at 81.6%, PTSD at 80.0%, Anxiety at 77.5%, and Parkinson’s at AUC 0.97. These figures are validated through published clinical research. Scienza Health never fabricates or approximates accuracy claims.

digitalhumanOS™ is trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events from clinical settings. This dataset is the largest of its kind purpose-built for PAC/LTC clinical screening.

No. GIA® operates within a 5-layer governance framework with mandatory human-in-the-loop review. She delivers screening results to the clinician in 60 seconds. The clinician reviews and submits — no result enters the clinical record without human approval.

GIA® analyzes over 2,500 speech biomarkers per conversation, including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators. During video sessions, she also captures 436 visual data points from facial micro-expressions and body movement.

GIA® screens for 46 conditions prevalent in SNFs, including cognitive impairment, MCI, Alzheimer’s disease, Parkinson’s disease, depression, PTSD, anxiety, bipolar disorder, sleep disorders, and substance abuse. The platform uses voice and speech biomarkers to detect subtle changes, enabling early identification and intervention.

Voice biomarker analysis offers an objective alternative to subjective questionnaires. It reduces staff and resident bias, captures subtle pre-symptomatic changes, and can be administered more frequently with less burden. This provides a more consistent and sensitive longitudinal view of cognitive and mental health.

Yes. GIA® detects pre-symptomatic indicators through vocal biomarker analysis. Changes in vocal prosody — reduced pitch variability, slower speech rate, altered pause patterns — can signify depressive states before a resident self-reports or displays overt symptoms, enabling proactive clinical assessment.

GIA® employs machine learning algorithms to analyze acoustic and linguistic features from speech. These voice biomarkers correlate with neuropathological changes associated with cognitive and mood disorders. The platform analyzes patterns in pitch, tone, rhythm, and word choice to generate an objective risk score.

Peer-reviewed validation shows 81.6% accuracy for depression detection via voice biomarker analysis. The platform is FDA-registered and trained on 12.3 million longitudinal PAC/LTC patient records. A clinician reviews every result before it enters the clinical record.

Zero staff time during screening. GIA® conducts the conversation independently via video, voice, or landline. A staff member initiates the screening on a tablet or device. The clinician reviews results in under 2 minutes. No trained screening staff required.

GIA® integrates natively with PointClickCare for real-time write-back of screening results, structured medical notes, full conversation transcripts, and recorded patient video. No manual data entry required. Scienza Health is a verified partner on the PointClickCare Marketplace.

Facilities see ROI through early detection of previously missed conditions (projected $180K–$240K in new CPT reimbursement for a 200-bed SNF), reduced rehospitalizations, recovered clinician hours, and improved CMS quality metrics. All projections modeled from published benchmarks.

Yes. GIA® provides objective screening data for cognition and mood that supports MDS 3.0 sections C1300 (cognitive function) and D0100–D0600 (mood). The quantitative evidence informs more accurate and defensible coding for PDPM classification.

GIA® documents every screening interaction with timestamped results, structured notes, and the full conversation record. This automated documentation supports psychotropic medication monitoring requirements under F-Tag 605, creating a defensible audit trail for CMS surveys.

GIA® is fully HIPAA compliant. All resident data is encrypted in transit and at rest using AES-256 encryption. The platform runs on Samsung Knox-secured devices and operates within a SOC 2-certified cloud infrastructure with strict access controls and regular security audits.

FDA device establishment registration with the FDA demonstrates that the device is substantially equivalent to a legally marketed predicate device. It validates the platform for clinical use in screening, distinguishing it from wellness apps and confirming it meets regulatory standards for safety and performance.

Accurate condition detection improves the clinical quality metrics that drive CMS star ratings. By identifying previously undetected cognitive and behavioral conditions, GIA® helps facilities improve screening rates, reduce rehospitalizations, and strengthen documentation — all factors in the five-star quality rating system.

GIA® screenings support CPT 96127 (brief behavioral assessment, $6–$11), CPT 96116 (neurobehavioral status exam, $94–$131), and CPT 99309 (subsequent nursing facility care, approximately $100). The platform documents the billable event and prepares CPT-coded results for clinician review.

GIA® screens for conditions that drive psychotropic prescribing — depression, anxiety, PTSD, bipolar disorder — and provides documented screening evidence. This supports gradual dose reduction protocols and F-Tag 605 requirements by ensuring behavioral health conditions are properly identified and monitored.